These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 3100612)

  • 1. Ceftazidime, a broad spectrum cephalosporin with activity against Ps. aeruginosa.
    O'Callaghan H
    J Hyg Epidemiol Microbiol Immunol; 1986; 30(4):449-53. PubMed ID: 3100612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro properties of ceftazidime, a highly active broad-spectrum cephalosporin with antipseudomonal activity.
    Harper PB
    Clin Ther; 1984; 6(4):411-24. PubMed ID: 6432324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative activity of ceftazidime and four other cephalosporins against gram-negative bacteria and their sensitivity to beta-lactamases.
    Galante D; Esposito S; Barba D; Pennucci C; Limauro D; Scioli C
    Chemioterapia; 1984 Aug; 3(4):250-4. PubMed ID: 6398123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro susceptibility pattern of cephalosporin-resistant Gram-negative bacteria.
    Punpanich W; Tantichattanon W; Wongwatcharapaiboon S; Treeratweeraphong V
    J Med Assoc Thai; 2008 Oct; 91 Suppl 3():S21-7. PubMed ID: 19255989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
    Jones RN; Sader HS; Fritsche TR; Pottumarthy S
    Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cefsulodin and ceftazidime, two antipseudomonal cephalosporins.
    Smith BR
    Clin Pharm; 1984; 3(4):373-85. PubMed ID: 6380902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of newer broad spectrum beta-lactam antibiotics against enterobacteriaceae and non-fermenters: a report from Austrian intensive care units. Austrian Carbapenem Susceptibility Surveillance Group.
    Krause R; Mittermayer H; Feierl G; Allerberger F; Wendelin I; Hirschl A; Reisinger EC
    Wien Klin Wochenschr; 1999 Jul; 111(14):549-54. PubMed ID: 10467641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antimicrobial activity of cefepime tested against ceftazidime-resistant Gram-negative clinical strains from North American Hospitals: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
    Pfaller MA; Sader HS; Fritsche TR; Jones RN
    Diagn Microbiol Infect Dis; 2006 Sep; 56(1):63-8. PubMed ID: 16650951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Analysis of drug resistance spectrum and its mechanism in 1017 clinical bacterial isolates].
    Geng SN; Rui YY; Wang Q; Mou CH; Zhou XH; Zhang J
    Di Yi Jun Yi Da Xue Xue Bao; 2005 Dec; 25(12):1529-32, 1545. PubMed ID: 16361155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antimicrobial profile of ceftazidime: the situation in three larger hospitals in Prague between 1981 and 1983.
    Hejzlar M; Sedmidubský V; Procházková A; Dvorský V; Stastná L; Paroubek M; Kotasová M; Puchmayerová M; Silarová J; Gleichová L
    J Hyg Epidemiol Microbiol Immunol; 1984; 29(3):311-5. PubMed ID: 6443365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Monitoring of bacteria resistance in burn patients].
    Zhang M; Xu X; Liao P
    Zhonghua Wai Ke Za Zhi; 1999 May; 37(5):278-81. PubMed ID: 11829839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concentration-dependency of beta-lactam-induced filament formation in Gram-negative bacteria.
    Buijs J; Dofferhoff AS; Mouton JW; Wagenvoort JH; van der Meer JW
    Clin Microbiol Infect; 2008 Apr; 14(4):344-9. PubMed ID: 18261128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of inoculum size on sensitivity and specificity of the double-disk synergy test for the detection of wide-spectrum beta-lactamases].
    Bedenić B; Boras A
    Lijec Vjesn; 2001; 123(11-12):293-6. PubMed ID: 11930754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Surveillance of antimicrobial resistance among nosocomial gram-negative pathogens from 15 teaching hospitals in China in 2005].
    Yang QW; Xu YC; Chen MJ; Hu YJ; Ni YX; Sun JY; Yu YS; Kong HS; He L; Wu WY; Ye HF; Yang YM; Zhu LN; Guo SH; Ji P; Zhu ZH; Ren JK; Zhang LX; Sun ZY; Zhu XH; Tong MQ; Zhao WS; Mei YN; Liu Y; Zhang ZJ; Duan Q; Li D; Liu PP; Wang J; Han LX; Wang H; Xie XL
    Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(39):2753-8. PubMed ID: 18167265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of sulperazon against recent isolates of ceftazidime-resistant bacteria.
    Lim VK; Halijah MY
    Med J Malaysia; 2001 Sep; 56(3):365-9. PubMed ID: 11732084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Antimicrobial susceptibility pattern of nosocomial gram negative pathogens: results from MYSTIC study in Hacettepe University Adult Hospital (2000-2004)].
    Zarakolu P; Hasçelik G; Unal S
    Mikrobiyol Bul; 2006 Jul; 40(3):147-54. PubMed ID: 17001842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Sensitivity of Pseudomonas aeruginosa and Klebsiella spp. to ceftazidime. Current status in France].
    Thabaut A; Acar J; Arlet G; Berardi-Grassias L; Bergogne-Bérézin E; Brun Y; Buisson Y; Chabanon G; Cluzel R; Courtieu A
    Presse Med; 1988 Oct; 17(37):1895-9. PubMed ID: 2973580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparison of the in vitro activity of ceftazidime: in culture, in serum and in combination with granulocytes].
    Daschner FD; Bassler M; Grundau D; Dieterle L; Just HM
    Immun Infekt; 1983 Nov; 11(6):221-8. PubMed ID: 6439624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In-vitro and in-vivo antibacterial activities of E1040, a new cephalosporin with potent antipseudomonal activity.
    Hiruma R; Otsuki M; Tashima M; Obana Y; Nishino T
    J Antimicrob Chemother; 1990 Dec; 26(6):769-81. PubMed ID: 2127928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. L-658,310, a new injectable cephalosporin. I. In vitro antibacterial properties.
    Weissberger BA; Abruzzo GK; Fromtling RA; Gill C; Ponticas S; Valiant ME; Shungu DL; Gadebusch HH
    J Antibiot (Tokyo); 1989 May; 42(5):795-806. PubMed ID: 2498277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.